FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.405,73 +1.645,15 (+2,71%)
Novozymes A/S (NVZMF)
| Chiusura precedente | 60,75 |
| Aperto | 60,75 |
| Denaro | 60,01 x 40000 |
| Domanda | 65,01 x 40000 |
| Min-Max giorno | 60,73 - 60,75 |
| Intervallo di 52 settimane | 38,85 - 65,40 |
| Volume | |
| Media Volume | 632 |
| Capitalizzazione | 28,992B |
| Beta (mensile su 5 anni) | 0,52 |
| Rapporto PE (ttm) | 38,13 |
| EPS (ttm) | 1,58 |
| Prossima data utili | 28 ago 2024 |
| Rendimento e dividendo (futuro) | 0,88 (1,46%) |
| Data ex dividendo | 01 mag 2024 |
| Stima target 1A | N/D |
GlobeNewswireNovozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
- GlobeNewswire
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
- GlobeNewswire
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing. COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the fi
